ATE348153T1 - Methode für die direkte gewinnung und amplifikation von integrierten viren aus zellulärer gewebe-dna - Google Patents
Methode für die direkte gewinnung und amplifikation von integrierten viren aus zellulärer gewebe-dnaInfo
- Publication number
- ATE348153T1 ATE348153T1 AT03252519T AT03252519T ATE348153T1 AT E348153 T1 ATE348153 T1 AT E348153T1 AT 03252519 T AT03252519 T AT 03252519T AT 03252519 T AT03252519 T AT 03252519T AT E348153 T1 ATE348153 T1 AT E348153T1
- Authority
- AT
- Austria
- Prior art keywords
- amplification
- cellular tissue
- tissue dna
- direct obtaining
- integrated viruses
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title abstract 2
- 230000003321 amplification Effects 0.000 title 1
- 230000001413 cellular effect Effects 0.000 title 1
- 238000003199 nucleic acid amplification method Methods 0.000 title 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 108091092356 cellular DNA Proteins 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37646902P | 2002-04-29 | 2002-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE348153T1 true ATE348153T1 (de) | 2007-01-15 |
Family
ID=29215906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03252519T ATE348153T1 (de) | 2002-04-29 | 2003-04-22 | Methode für die direkte gewinnung und amplifikation von integrierten viren aus zellulärer gewebe-dna |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7235393B2 (de) |
| EP (1) | EP1359217B1 (de) |
| JP (1) | JP3943048B2 (de) |
| AT (1) | ATE348153T1 (de) |
| AU (1) | AU2003231031A1 (de) |
| CA (1) | CA2426283C (de) |
| DE (1) | DE60310297T2 (de) |
| ES (1) | ES2280694T3 (de) |
| WO (1) | WO2003093460A1 (de) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX359371B (es) | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
| US7510872B2 (en) * | 2003-02-26 | 2009-03-31 | Nationwide Children's Hospital | Recombinant adeno-associated virus production |
| ES2525067T3 (es) | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
| US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| WO2011126808A2 (en) | 2010-03-29 | 2011-10-13 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| EP3444346B1 (de) | 2010-04-23 | 2022-07-27 | University of Massachusetts | Aav-basierte behandlung von cholesterinerkrankungen |
| EP2561073B1 (de) | 2010-04-23 | 2016-08-24 | University of Massachusetts | Auf das zentralnervensystem abzielende vektoren und verfahren zu ihrer verwendung |
| US9546369B2 (en) | 2010-04-23 | 2017-01-17 | University Of Massachusetts | Multicistronic expression constructs |
| EP2605798A1 (de) | 2010-07-12 | 2013-06-26 | Universidad Autònoma de Barcelona | Gentherapiezusammensetzung für die behandlung von diabetes |
| EP3318635A1 (de) | 2011-04-21 | 2018-05-09 | University of Massachusetts | Raav-basierte zusammensetzungen und verfahren zur behandlung von alpha-1-anti-trypsin-mangel |
| EP2692868A1 (de) | 2012-08-02 | 2014-02-05 | Universitat Autònoma De Barcelona | Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe |
| US10072251B2 (en) | 2014-02-19 | 2018-09-11 | University Of Massachusetts | Recombinant AAVS having useful transcytosis properties |
| CA2942515C (en) | 2014-03-18 | 2025-12-09 | University Of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
| WO2015164786A1 (en) | 2014-04-25 | 2015-10-29 | University Of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
| WO2015187825A2 (en) | 2014-06-03 | 2015-12-10 | University Of Massachusetts | Compositions and methods for modulating dysferlin expression |
| EP3151866B1 (de) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimäre kapside |
| EP3200830B1 (de) | 2014-10-03 | 2020-09-09 | University of Massachusetts | Hocheffiziente bibliotheksidentifizierte aav-vektoren |
| US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
| CN107073051B (zh) | 2014-10-21 | 2021-08-24 | 马萨诸塞大学 | 重组aav变体及其用途 |
| RU2716991C2 (ru) | 2014-11-05 | 2020-03-17 | Вояджер Терапьютикс, Инк. | Полинуклеотиды aadc для лечения болезни паркинсона |
| WO2016077687A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| US11033638B2 (en) | 2015-01-07 | 2021-06-15 | Universität Autonoma De Barcelona | Single-vector gene construct comprising insulin and glucokinase genes |
| EP3256170B1 (de) | 2015-02-13 | 2020-09-23 | University of Massachusetts | Zusammensetzungen und verfahren zur transitorischen freisetzung von polypeptiden |
| US11046955B2 (en) | 2015-04-24 | 2021-06-29 | University Of Massachusetts | Modified AAV constructs and uses thereof |
| EP3364997B1 (de) | 2015-10-22 | 2024-01-17 | University of Massachusetts | Aspartoacylase gentherapie zur behandlung von morbus canavan |
| WO2017070516A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Prostate-targeting adeno-associated virus serotype vectors |
| EP3384035A4 (de) | 2015-12-02 | 2019-08-07 | Voyager Therapeutics, Inc. | Assays zum nachweis von aav-neutralisierenden antikörpern |
| CA3011939A1 (en) | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
| CA3012344A1 (en) | 2016-02-12 | 2017-08-17 | University Of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
| US11207426B2 (en) | 2016-04-05 | 2021-12-28 | University Of Massachusetts | Compositions and methods for selective inhibition of grainyhead-like protein expression |
| US11413356B2 (en) | 2016-04-15 | 2022-08-16 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3448874A4 (de) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Zusammensetzungen zur behandlung einer erkrankung |
| KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| KR102427379B1 (ko) | 2016-05-18 | 2022-08-02 | 보이저 테라퓨틱스, 인크. | 헌팅톤 질환을 치료하기 위한 조성물 및 방법 |
| US11882815B2 (en) | 2016-06-15 | 2024-01-30 | University Of Massachusetts | Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells |
| WO2018044933A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| AU2017341849B2 (en) | 2016-10-13 | 2024-03-21 | University Of Massachusetts | AAV capsid designs |
| JP2020518258A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法 |
| JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハンチントン病治療組成物および方法 |
| US11859179B2 (en) | 2017-05-09 | 2024-01-02 | University Of Massachusetts | Methods of treating amyotrophic lateral sclerosis (ALS) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| EP3808849A1 (de) | 2017-08-03 | 2021-04-21 | Voyager Therapeutics, Inc. | Zusammensetzungen und verfahren zur aav-freisetzung |
| CN111448321A (zh) | 2017-09-22 | 2020-07-24 | 马萨诸塞大学 | Sod1双表达载体及其用途 |
| AU2018338728B2 (en) | 2017-09-29 | 2025-01-02 | Centre National De La Recherche Scientifique (Cnrs) | Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery |
| EP3697908A1 (de) | 2017-10-16 | 2020-08-26 | Voyager Therapeutics, Inc. | Behandlung von amyotropher lateralsklerose (als) |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
| US20190256867A1 (en) | 2018-02-01 | 2019-08-22 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring pah gene function and methods of use thereof |
| JP7244547B2 (ja) | 2018-02-19 | 2023-03-22 | ホモロジー・メディシンズ・インコーポレイテッド | Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法 |
| KR20210019996A (ko) | 2018-05-15 | 2021-02-23 | 보이저 테라퓨틱스, 인크. | 파킨슨병의 치료를 위한 조성물 및 방법 |
| WO2019236995A1 (en) | 2018-06-08 | 2019-12-12 | University Of Massachusetts | Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells |
| WO2019241486A1 (en) | 2018-06-13 | 2019-12-19 | Voyager Therapeutics, Inc. | Engineered 5' untranslated regions (5' utr) for aav production |
| CN112770812A (zh) | 2018-07-24 | 2021-05-07 | 沃雅戈治疗公司 | 产生基因治疗制剂的系统和方法 |
| EP3856762A1 (de) | 2018-09-28 | 2021-08-04 | Voyager Therapeutics, Inc. | Frataxin-expressionskonstrukte mit gentechnisch veränderten promotoren und verfahren zu deren verwendung |
| WO2020072849A1 (en) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
| WO2020072844A1 (en) | 2018-10-05 | 2020-04-09 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding aav production proteins |
| CN113166781A (zh) | 2018-10-15 | 2021-07-23 | 沃雅戈治疗公司 | 在杆状病毒/Sf9系统中大规模生产rAAV的表达载体 |
| WO2020160508A1 (en) | 2019-01-31 | 2020-08-06 | Oregon Health & Science University | Methods for using transcription-dependent directed evolution of aav capsids |
| ES2948620T3 (es) | 2019-07-10 | 2023-09-14 | Masonic Medical Res Laboratory | Vgll4 con elemento regulador CIS de UCP-1 y método de uso del mismo |
| TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| US11926842B2 (en) | 2021-02-02 | 2024-03-12 | University Of Massachusetts | Use of inverted terminal repeats (ITRS) from adeno-associated virus serotypes 8 and RH.39 in gene therapy vectors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6261834B1 (en) | 1991-11-08 | 2001-07-17 | Research Corporation Technologies, Inc. | Vector for gene therapy |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| EP1024198A3 (de) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenovirenvectors zur Gentherapie der Hämophilien |
| DK0814154T3 (da) | 1993-09-15 | 2009-08-31 | Novartis Vaccines & Diagnostic | Rekombinante alfavirusvektorer |
| US5773289A (en) | 1995-06-06 | 1998-06-30 | University Of Pittsburgh | AAV directed targeted integration |
| US6086913A (en) | 1995-11-01 | 2000-07-11 | University Of British Columbia | Liposomal delivery of AAV vectors |
| EP1003895A2 (de) * | 1997-07-10 | 2000-05-31 | Hepavec AG fur Gentherapie | Klonierungsvektoren für die herstellung von adenoviralen minimalviren |
| CA2375098A1 (en) | 1999-06-02 | 2000-12-14 | Trustees Of The University Of Pennsylvania | Compositions and methods useful for production of recombinant viruses which require helper viruses |
| US6815180B1 (en) * | 1999-10-15 | 2004-11-09 | Kim Jin-Woo | Human cervical cancer 1 protooncogene and protein encoded therein |
| TWI289158B (en) * | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
| MX359371B (es) | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
-
2003
- 2003-04-22 AT AT03252519T patent/ATE348153T1/de not_active IP Right Cessation
- 2003-04-22 JP JP2003116878A patent/JP3943048B2/ja not_active Expired - Lifetime
- 2003-04-22 US US10/420,284 patent/US7235393B2/en not_active Expired - Lifetime
- 2003-04-22 ES ES03252519T patent/ES2280694T3/es not_active Expired - Lifetime
- 2003-04-22 AU AU2003231031A patent/AU2003231031A1/en not_active Abandoned
- 2003-04-22 DE DE60310297T patent/DE60310297T2/de not_active Expired - Lifetime
- 2003-04-22 CA CA002426283A patent/CA2426283C/en not_active Expired - Lifetime
- 2003-04-22 EP EP03252519A patent/EP1359217B1/de not_active Expired - Lifetime
- 2003-04-22 WO PCT/US2003/012405 patent/WO2003093460A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE60310297D1 (de) | 2007-01-25 |
| US7235393B2 (en) | 2007-06-26 |
| ES2280694T3 (es) | 2007-09-16 |
| JP3943048B2 (ja) | 2007-07-11 |
| EP1359217B1 (de) | 2006-12-13 |
| AU2003231031A1 (en) | 2003-11-17 |
| WO2003093460A1 (en) | 2003-11-13 |
| CA2426283A1 (en) | 2003-10-29 |
| CA2426283C (en) | 2006-06-27 |
| DE60310297T2 (de) | 2007-06-06 |
| EP1359217A1 (de) | 2003-11-05 |
| JP2003310252A (ja) | 2003-11-05 |
| US20030207259A1 (en) | 2003-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE348153T1 (de) | Methode für die direkte gewinnung und amplifikation von integrierten viren aus zellulärer gewebe-dna | |
| DE60311961D1 (de) | Detektionsverfahren für papillomavirus mrna | |
| NO20000513D0 (no) | Oligonukleotid-reverstranskripsjonsprimere for effektiv detektering av HIV-1 og HIV-2 og metoder for anvendelse derav | |
| DE60238493D1 (de) | Is von seltenen zellen verwendete markierte zellen | |
| ATE469219T1 (de) | Zusammensetzungen, methoden und reagentien zur nukleinsäureisolierung mittels oberflächenaktiven substanzen und proteasen | |
| ATE508635T1 (de) | Virusvektoren und ihre verwendung bei therapeutischen methoden | |
| EP1026262A3 (de) | Oligonukleotidprimer zur effizienten Detektion von Hepatitis C Virus (HCV) sowie Verwendungsverfahren | |
| IL221602A0 (en) | A method of detecting and/or identifying adeno-associted virus (aav) sequences and isolating novel sequences identified thereby | |
| DE69632466D1 (de) | Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen | |
| BR0212469A (pt) | Método para multiplicação de vìrus em cultura de célula | |
| DE60330399D1 (de) | Trichmikroskopie, kultur und polymerasekettenreaktion unter verwendung prozessierter klinischer proben und kit davon | |
| ATE529401T1 (de) | Aminocyclohexylether-verbindungen und deren verwendung | |
| AU2003226052A8 (en) | Methods for detecting abnormally methylated nucleic acid in heterogeneous biological samples | |
| PT1283907E (pt) | Metodo para o diagnostico de cancros | |
| ATE466080T1 (de) | Formulierungen und verfahren zum denaturieren von proteinen | |
| DE69935999D1 (de) | Methoden zur introduktion heterologer zellen in fische | |
| ATE513851T1 (de) | Menschliches gen zur fruchtbarkeit entscheidend | |
| PT1035220E (pt) | Iniciadores oligonucleotidicos para deteccao eficiente em multiplex do virus da hepatite c (hcv) e do virus da imunodeficiencia humana e seus metodos de utilizacao | |
| EP1526176A3 (de) | Vorrichtungen und Methoden zur RNA Isolation. | |
| WO1999039009A8 (en) | Processes for isolating, amplifying and characterizing dna | |
| DE69938774D1 (de) | Verfahren zur isolierung, amplifizierung und charakterisierung von dns | |
| DE69913533D1 (de) | Reagentien für cyp2d fluoreszenztest | |
| DE602004028862D1 (de) | Der nukleinsäuren von hiv-1 und hiv-2 | |
| DE502004003467D1 (de) | Von vca-p18 kapsidantigen des epstein-barr-virus abgeleitete peptide und ihre verwendung | |
| DE69940848D1 (de) | (-)-strang rns virusvektor für nervenzellen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |